Committee raises reimbursement to encourage clinics to offer new RSV monoclonal antibody for infants

Representative Zach Gramlich (Fort Smith) described his bill to address access barriers to a newly available monoclonal antibody that prevents severe RSV illness in infants entering their first RSV season. He said his own family’s difficulty obtaining the preventive injection prompted the legislation.

“This is how it's affected me personally,” Gramlich said, explaining repeated attempts to secure the shot for his newborn and concluding that many clinic offices did not stock the product because the reimbursement and administrative fee made it a money‑losing proposition for providers.

Nut graf: The committee approved the bill, which places the prophylactic monoclonal antibody on the state reimbursement schedule used for vaccines and raises the administrative reimbursement from about $13.14 to $19.54 — a sponsor estimate intended to cover clinic costs and induce more providers to stock and offer the single-dose product. Witness testimony from the Arkansas chapter of the American Academy of Pediatrics characterized the measure as a way to increase access and reduce RSV hospitalizations among infants.

Key details from testimony and Q&A:

- Product and dosing: Gramlich described the product as a monoclonal antibody (passive immunoprophylaxis), given as a single injection to protect infants for roughly six months during RSV season; it was not characterized as an mRNA or traditional vaccine.

- Reimbursement math: Gramlich said the bill raises reimbursement from $13.14 to $19.54. He said the Medicaid match would reduce the state share to under $2 per dose in his estimate. He and a pediatric witness argued that avoiding even a single RSV hospitalization (conservatively estimated at $5,000) would offer a strong return on investment if a modest number of shots prevented one hospitalization.

- Fiscal and agency stance: A representative from the Arkansas chapter of the American Academy of Pediatrics testified in support and described the measure as having a good return on investment for Medicaid; committee members noted a minimal fiscal impact on committee record and DHS said it was neutral to the bill during discussion.

- Vote: The committee passed the bill by voice vote with no recorded roll-call tally.

What the bill does and does not do: The bill does not mandate use; it adjusts reimbursement and places the product in the vaccines-for-children reimbursement program to reduce clinics’ financial disincentive to stock and administer the shot. Sponsor statements note the aim is to increase access for infants at high risk of severe RSV disease.

Quotes (selected):

- “If we can keep 1 kid out of the hospital out of a hundred and 28 shots, it's a 610% return on investment,” — Representative Zach Gramlich (sponsor estimate during Q&A).

- “This is not our bill, but representative Grammlich came to us with this issue… it’s a simple shot that helps keep them out of the hospital,” — Anna Strong, Arkansas chapter, American Academy of Pediatrics (witness).

Next steps: The bill passed committee and will move forward; implementation will require DHS/Medicaid processes to adopt the updated reimbursement and providers to adjust stocking practices.